Business
Half Yearly Report to 31 March 2019
Half Yearly Report to 31 March 2019.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 7534Z IXICO plc 22 May 2019 \n\n22nd May 2019\nIXICO plc\n(\"IXICO\", the \"Company\" or the \"Group\")\n \nHalf Yearly Report to 31 March 2019\n \n£3.4M H1 2019 Revenue\n22% revenue growth on H1 2018\n£21.2M order book\nBreakeven \nStrong closing cash balance of £7.5M\n \nIXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces its unaudited interim results for the six months ended 31 March 2019.\n \nHighlights\n \nCommercial and Operational\n· £5.2M new and expanded contracts won across H1 2019.\n· Strong contracted order book of £21.2M* as at 31 March 2019.\n· Broadened expertise in neurological disease areas and diversification of biopharmaceutical clients.\n· Chosen as partner for King's College London's UK Government-funded Medical Imaging & Artificial Intelligence Centre.\n \nFinancial \n· Revenue of £3.4M; 22% increase on prior period (H1 2018: £2.8M**).\n· Revenue excluding foreign exchange of £3.3M*; 21% increase on prior period (H1 2018: £2.7M**).\n· Gross margin expanded by +610 bps** over H1 2018 to 66.3%.\n· EBITDA of £0.1M driven by strong operational leverage at gross margin level (H1 2018: negative £0.4M**).\n· Operating profit of £0.1M (H1 2018: loss of £0.5M**).\n· Profit per share of 0.5p (H1 2018: negative 1.5p**).\n· Closing cash of £7.5M.\n \n*Calculated using the fixed foreign exchange at the time of contract signing for each individual multi-year contract.\n**Adjusted to reflect the adoption of IFRS 15 'Revenue from Contracts with Customers'.\n \nGiulio Cerroni, CEO of IXICO, said: \"The first half of 2019 has been another...